RecruitingPhase 3NCT07217587

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Efficacy and Safety of Nipocalimab vs Efgartigimod for Patients With Generalized Myasthenia Gravis in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab

Sponsor

Janssen Research & Development, LLC

Enrollment

115 participants

Start Date

Jan 5, 2026

Study Type

INTERVENTIONAL

Conditions

Myasthenia Gravis

Summary

The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).

Eligibility

Min Age: 18 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Efgartigimod and a drug called Nipocalimab for people with myasthenia gravis. The study is currently recruiting participants at 15 locations. People eligible for this study include aged 18 Years to 74 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNipocalimab

Nipocalimab will be administered intravenously.

DRUGEfgartigimod

Efgartigimod will be administered intravenously.

Locations(15)

Neurology Center of North Orange County

Fullerton, California, United States

The Neurology Group

Pomona, California, United States

Advanced Neurology of Colorado

Fort Collins, Colorado, United States

University of Connecticut

Farmington, Connecticut, United States

SFM Clinical Research LLC

Boca Raton, Florida, United States

HSHS St. Elizabeth's Hospital

O'Fallon, Illinois, United States

Josephson Wallack Munshower Neurology, PC

Indianapolis, Indiana, United States

Tulane Center for Clinical Research

New Orleans, Louisiana, United States

Henry Ford Hospital

Detroit, Michigan, United States

Velocity Clinical Research, Inc.

Raleigh, North Carolina, United States

Atrium Health Wake Forest Baptist

Winston-Salem, North Carolina, United States

Texas Neurology

Dallas, Texas, United States

Rambam Medical Center

Haifa, Israel

Sourasky Medical Center

Tel Aviv, Israel

HOCH Health Ostschweiz Kantonsspital St.Gallen

Sankt Gallen, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07217587

Related Trials

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT0622020135 locations

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

NCT076737442 locations

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT0619388922 locations

Capturing Key MG-symptoms Using Smartphone Recordings.

NCT067434902 locations

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

NCT0526527319 locations